FENOLDOPAM

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H16ClNO3
Molecular Weight	305.756
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(C=C1)C2CNCCC3=C(Cl)C(O)=C(O)C=C23

InChI

InChIKey=TVURRHSHRRELCG-UHFFFAOYSA-N

InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2

HIDE SMILES / InChI

Molecular Formula	C16H16ClNO3
Molecular Weight	305.756
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf | https://www.drugbank.ca/drugs/DB00800

Fenoldopam (marketed under the brand name Corlopam) is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. Fenoldopam Mesylate Injection, USP is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D1 receptor 101 Target ID: CHEMBL2056 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/9784114 \| https://www.ncbi.nlm.nih.gov/pubmed/7525564	Agonist 2678		40.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf	Primary		Approved 8429	CORLOPAM Approved Use Adult Patients: Fenoldopam is indicated for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. Transition to oral therapy with another agent can begin at any time after blood pressure is stable during fenoldopam infusion. Pediatric Patients: Fenoldopam is indicated for the in-hospital, short-term (up to 4 hours) reduction in blood pressure. Launch Date 1997

C_max

Value	Dose	Co-administered	Analyte	Population
10.9 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1673097	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FENOLDOPAM plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FED
26.5 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1673097	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FENOLDOPAM plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
26.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1673097	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FENOLDOPAM plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FED
44.7 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1673097	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FENOLDOPAM plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1673097	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FENOLDOPAM plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FED
2.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1673097	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		FENOLDOPAM plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
1.5 ug/kg/min single, intravenous Highest studied dose Dose: 1.5 ug/kg/min Route: intravenous Route: single Dose: 1.5 ug/kg/min Sources: https://pubmed.ncbi.nlm.nih.gov/1967592 Page: 1-61	unhealthy, 46±3 n = 9 Health Status: unhealthy Condition: Hypertension Age Group: 46±3 Sex: M+F Population Size: 9 Sources: https://pubmed.ncbi.nlm.nih.gov/1967592 Page: 1-61	Sources: https://pubmed.ncbi.nlm.nih.gov/1967592 Page: 1-61
0.8 ug/kg/min single, intravenous Recommended Dose: 0.8 ug/kg/min Route: intravenous Route: single Dose: 0.8 ug/kg/min Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf Page: p.1	Disc. AE: Tachycardia, Hypokalemia... AEs leading to discontinuation/dose reduction: Tachycardia Hypokalemia Anaphylactic reaction Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Anaphylactic reaction	Disc. AE	0.8 ug/kg/min single, intravenous Recommended Dose: 0.8 ug/kg/min Route: intravenous Route: single Dose: 0.8 ug/kg/min Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf Page: p.1
Hypokalemia	Disc. AE	0.8 ug/kg/min single, intravenous Recommended Dose: 0.8 ug/kg/min Route: intravenous Route: single Dose: 0.8 ug/kg/min Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf Page: p.1
Tachycardia	Disc. AE	0.8 ug/kg/min single, intravenous Recommended Dose: 0.8 ug/kg/min Route: intravenous Route: single Dose: 0.8 ug/kg/min Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf Page: p.1

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5002	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5002
ChemicalBook	CB6729842	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6729842
MolPort	MolPort-006-167-637	https://www.molport.com/shop/molecule-link/MolPort-006-167-637
Selleck Chemicals	fenoldopam-corlopam	http://www.selleckchem.com/products/fenoldopam-corlopam.html
eMolecules	36518021	https://www.emolecules.com/cgi-bin/more?vid=36518021

PubMed

Title	Date	PubMed
Evaluation of plasma von Willebrand factor as a biomarker for acute arterial damage in rats.	2000 Sep-Oct	11026604
Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.	2001	12439366
Radiocontrast-induced acute renal failure: allocations and outcomes.	2001	12439362
Use of fenoldopam for prevention of radiocontrast nephropathy in the cardiac catheterization laboratory: a case series.	2001 Apr	12053301
Hypertensive emergencies.	2001 Apr	11450325
Histopathological and immunohistochemical studies on arteritis induced by fenoldopam, a vasodilator, in rats.	2001 Apr	11370730
Dopamine-1 receptor stimulation attenuates the vasoconstrictive response to gut ischemia.	2001 Aug	11457770
Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.	2001 Jan-Feb	11489662
D(1) dopamine receptor regulation of NHE3 during development in spontaneously hypertensive rats.	2001 Jun	11353667
Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.	2002 Apr 15	11950448
A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam.	2002 Feb	11835641
Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.	2002 Jul	12180796
Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats.	2002 May	12069360
Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy.	2002 May	12040355
Stability of fenoldopam mesylate in two infusion solutions.	2002 May 1	12004463
In vivo effects of fenoldopam on autonomic nervous system after inhibition or activation of ganglionic transmission.	2002 May 31	12063080
The third strike.	2002 Nov	12410498
Desensitization of human renal D1 dopamine receptors by G protein-coupled receptor kinase 4.	2002 Sep	12164861
The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients.	2003	12556736
A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.	2003	12556733
Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass.	2003 Aug	12968238
Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.	2003 Dec	14695041
Monitoring renal oxygen supply in critically-ill patients using urinary oxygen tension.	2003 Dec	14633556
Amygdaloid D1 receptors are not linked to stimulation of adenylate cyclase.	2003 Dec 15	14556237
Acetylcysteine and fenoldopam. Promising new approaches for preventing effects of contrast nephrotoxicity.	2003 Jun	12830779
Fenoldopam treatment improves peripheral insulin sensitivity and renal function in STZ-induced type 2 diabetic rats.	2003 May	12797596
Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.	2003 May	12739990
Contrast agent--associated nephrotoxicity.	2003 May-Jun	12800130
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.	2003 Nov 5	14600187
Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats.	2003 Oct	12900438
N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.	2004 Aug 18	15312855
Optimization of intestinal mucosal oxygenation in shock: a role for medical therapy?	2004 Jan	14707603
Dopamine under alpha1-blockade, but not dopamine alone or fenoldopam, increases depressed gastric mucosal oxygenation.	2004 Jan	14707574
Periprocedural hypertension: current concepts in management for the vascular surgeon.	2004 Jul-Aug	15306955
Lessons in formulary management: the case of fenoldopam for radiographic contrast material-induced nephropathy.	2004 Jun	15222676
Prophylaxis of iodinated contrast media-induced nephropathy: a pharmacological point of view.	2004 Mar	15076008
Dopamine D1 receptor augmentation of D3 receptor action in rat aortic or mesenteric vascular smooth muscles.	2004 Mar	14769810

Patents

Sample Use Guides

In Vivo Use Guide

Adults: Initiate dosing at 0.01 to 0.3 mcg/kg/min by continuous infusion. Dosing can be increased in increments of 0.05 to 0.1 mcg/kg/minute every 15 minutes or longer until target blood pressure is reached. Dilute prior to administration Pediatrics: Initiate dosing at 0.2 mcg/kg/minute by continuous infusion and titrate dose by 0.3 to 0.5 mcg/kg/min every 20-30 minutes to a maximum dose of 0.8 mcg/kg/minute

Route of Administration: Intravenous

In Vitro Use Guide

Incubation of freshly isolated mouse kidney slices with the selective D(1)-like receptor agonists fenoldopam (10 uM) and SKF-38393 (10 uM) for 1 h induced NaPi-IIa internalization and reduced expression of NaPi-IIa in the brush border membrane (BBM).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:30:37 GMT 2023` Edited by `admin` on `Fri Dec 15 15:30:37 GMT 2023`
Record UNII	INU8H2KAWG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FENOLDOPAM

Official Name

English

FENOLDOPAM [MI]

Common Name

English

Fenoldopam [WHO-DD]

Common Name

English

CARLACOR

Brand Name

English

fenoldopam [INN]

Common Name

English

FENOLDOPAM [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66884